Journal of Viral Hepatitis最新文献

Cost-Effectiveness of Interventions to Improve Retention in Care for Chronic Hepatitis B in the United States 干预措施的成本效益，以提高在美国慢性乙型肝炎护理留置。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-04-12 DOI: 10.1111/jvh.70176

Irene Starinieri, Amit Chitnis, Robert J. Wong, Emily Yette, Hang Pham, Amy S. Tang, Samuel So, Mehlika Toy

{"title":"Cost-Effectiveness of Interventions to Improve Retention in Care for Chronic Hepatitis B in the United States","authors":"Irene Starinieri, Amit Chitnis, Robert J. Wong, Emily Yette, Hang Pham, Amy S. Tang, Samuel So, Mehlika Toy","doi":"10.1111/jvh.70176","DOIUrl":"10.1111/jvh.70176","url":null,"abstract":"<p>Monitoring and retention in care remain suboptimal for patients diagnosed with chronic hepatitis B (CHB) infection with only a minority receiving consistent follow-up. This study evaluates the cost-effectiveness of interventions aimed at improving long-term monitoring and retention in care among diagnosed CHB. A Markov model simulated outcomes for a cohort of 100,000 adults, comparing current practice to three interventions: EHR-based provider reminders, patient navigators and a combined strategy. Costs and quality-adjusted life years (QALYs) were evaluated from a healthcare perspective. All interventions were cost-effective, with weighted incremental cost-effectiveness ratios (US$/QALY) of US$8069 (EHR reminders), US$8416 (Patient Navigators) and US$8608 (Combined). Compared with current practice, a combined strategy would avert 1670 cases of compensated cirrhosis, 738 cases of decompensated cirrhosis, 1011 cases of hepatocellular carcinoma, 188 liver transplants, and 2058 CHB-related deaths in a cohort of 100,000. Structured interventions to improve CHB monitoring can deliver substantial health gains at modest costs. These findings can support policy initiatives to improve CHB care retention and highlight the importance of tailoring interventions to local healthcare capacity and population needs.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 5","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa-2b Versus Peginterferon Alfa-2b Monotherapy of HBeAg-Positive Chronic Hepatitis B in China 富马酸替诺福韦与聚乙二醇干扰素- α -2b从头联合治疗与聚乙二醇干扰素- α -2b单药治疗hbeag阳性慢性乙型肝炎的成本-效果

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-04-09 DOI: 10.1111/jvh.70170

Na Wei, Maobai Liu, Hongfu Cai, Na Li, Jing Yang, Shunmin Huang, Bin Zheng

{"title":"Cost-Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa-2b Versus Peginterferon Alfa-2b Monotherapy of HBeAg-Positive Chronic Hepatitis B in China","authors":"Na Wei, Maobai Liu, Hongfu Cai, Na Li, Jing Yang, Shunmin Huang, Bin Zheng","doi":"10.1111/jvh.70170","DOIUrl":"10.1111/jvh.70170","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic hepatitis B (CHB) refers to a global infectious disease caused by the hepatitis B virus. The treatment of CHB causes a heavy economic burden to society. To ensure the rational allocation of medical resources in the whole society and achieve the goal of patients' satisfaction and economy, this study aimed to evaluate the economics of de novo combination of tenofovir alafenamide fumarate (TAF) as the first-line nucleos(t)ide analogues (NAs) and peginterferon alfa-2b (PEG-IFNα-2b) versus PEG-IFNα-2b monotherapy of HBeAg-positive CHB in China. The Markov model was used to simulate the transition of HBeAg-positive CHB patients aged 30 in China under various health states using TreeAge Pro 2011 software. The cycle length was 1 year, and the cycle period of the model was 50 years. The model parameters included clinical efficacy, cost, transition probability and discount rate. Cost-effectiveness analysis was conducted through simulation of the total cost and quality adjusted life years (QALYs) of various treatment options through models. Simultaneously, one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were performed. De novo combination of TAF and PEG-IFNα-2b and PEG-IFNα-2b monotherapy resulted in 11.16 and 10.81 QALYs, with total costs of $55559.72 and $57670.23, respectively. De novo combination strategy for HBeAg-positive CHB patients can save costs and obtain more health outcomes. Sensitivity analyses showed the reliability of the results. From the perspective of the whole society, the de novo combination strategy of TAF and PEG-IFNα-2b for patients with HBeAg-positive CHB may be more cost-effective than PEG-IFNα-2b monotherapy.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 5","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147639374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk 与HBV感染易感性和肝细胞癌风险相关的遗传变异荟萃分析。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-04-05 DOI: 10.1111/jvh.70175

So Yoon Lee, Hyoung Doo Shin

{"title":"Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk","authors":"So Yoon Lee, Hyoung Doo Shin","doi":"10.1111/jvh.70175","DOIUrl":"10.1111/jvh.70175","url":null,"abstract":"<p>Hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) are serious medical problems worldwide. Today, many researchers believe that genetic variations play a major role in how easily someone gets infected and how the disease progresses over time. Although many genetic association studies have suggested various susceptibility loci, lack of consistent results across studies has limited clinical utility. We performed a comprehensive meta-analysis primarily involving East Asian cohorts. We analysed eight SNPs related to HBV infection and 11 SNPs related to HCC across multiple etiologic subgroups. We found that CD40 rs1883832 and C2 rs9267665 exhibited the strongest associations with susceptibility to HBV infection, with no heterogeneity. We found that HLA-DPA1 rs3077 and HLA-DQB1 rs2856718 were significantly associated with HBV infection susceptibility, though with considerable heterogeneity. In our HCC analyses, we found that certain risk variants are linked to specific causes. These include HBV, HCV, alcohol-related disease, and non-alcoholic fatty liver disease (NAFLD). Each cause seems to have its own genetic factors. Based on these results, our meta-analysis brings together many studies to give a clearer picture of the genetic factors that influence HBV infection and HCC in different etiologic pathways. We found that immune-related genes and HLA class II variants seem to have roles in HBV persistence, while metabolic gene variants are major contributors to HCC risk.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 5","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C Treatment 利用远程医疗参与低屏障丙型肝炎药物使用障碍农村患者的治疗。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-27 DOI: 10.1111/jvh.70173

Kristi C. Hill, Sherilyn Brinkley, Maria Latimer, Patricia Tichnell, Tracy Agee, Jackie Bittner, David L. Thomas, Mark S. Sulkowski, Oluwaseun Falade-Nwulia

{"title":"Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C Treatment","authors":"Kristi C. Hill, Sherilyn Brinkley, Maria Latimer, Patricia Tichnell, Tracy Agee, Jackie Bittner, David L. Thomas, Mark S. Sulkowski, Oluwaseun Falade-Nwulia","doi":"10.1111/jvh.70173","DOIUrl":"10.1111/jvh.70173","url":null,"abstract":"<div>\u0000 \u0000 <p>Despite overall decline in hepatitis C virus (HCV) incidence in the United States, incidence in rural areas has continued to increase, primarily driven by injection drug use. Models of HCV care serving people in rural areas are needed. The TRAnsporting Hep C Viral ELimination Services via Telemedicine (TRAVEL) Program was implemented to increase access to HCV care in rural Maryland through an integrated model of local nurse case management support and facilitated telemedicine embedded within a local health department. Between January 2018 and March 2024, 502 anti-HCV+ patients were referred to the program. Of those referred, 384 [76%] were linked to care, with the majority having a substance use disorder (SUD) diagnosis [236 (61%)]. Laboratory draws and challenges with subsequent phone contact were barriers to initial linkage of referred individuals. Among the 282 patients who completed baseline labs and had HCV viremia, 272 [96%] attended a provider visit, 262 [93%] initiated DAA therapy, 254 [90%] completed treatment, 188 [67%] completed HCV cure labs and 186 [66%] had confirmed HCV cure. There was no significant difference in treatment initiation and completion between patients with and without SUDs, but patients with SUD were significantly less likely to complete HCV cure labs [aOR 0.43 (0.21, 0.82)]. The TRAVEL Program achieved high retention in care and HCV cure rates; however, a quarter of referred patients were not linked to care, and laboratory draws were a barrier along the care continuum. Strategies to optimize linkage and laboratory evaluation are needed.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 5","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147521354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploration of a Model for Elimination of Hepatitis C in Women of Childbearing Age in Primary Hospitals in Southern China 中国南方基层医院育龄妇女丙型肝炎消除模式的探索

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-19 DOI: 10.1111/jvh.70153

Li Guo, Wenbin Wu, Wen Zhou, Ruiting Liang, Yan lin, Yuting Chen, Yuping Wu, Jing Fei, YingPing Chen, Liyun Ruan, Houyang Zeng, Bihua Gao

{"title":"Exploration of a Model for Elimination of Hepatitis C in Women of Childbearing Age in Primary Hospitals in Southern China","authors":"Li Guo, Wenbin Wu, Wen Zhou, Ruiting Liang, Yan lin, Yuting Chen, Yuping Wu, Jing Fei, YingPing Chen, Liyun Ruan, Houyang Zeng, Bihua Gao","doi":"10.1111/jvh.70153","DOIUrl":"10.1111/jvh.70153","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatitis C virus (HCV) can be transmitted from mother to child, although data on HCV elimination in women of childbearing age remain limited. This study aimed to evaluate an intervention model aligning with the ‘treatment as prevention’ strategy. The ‘Hepatitis C Prevention and Treatment Project for Women of Childbearing Age (15–49 years)’, launched in October 2022, strengthened the use of HCV-Ab screening, RNA testing, and treatment referral through multidisciplinary hospital collaborations. Key indicators (screening, RNA testing, and treatment rates) were compared between the pre-intervention (October 2021–September 2022) and post-intervention (October 2022–September 2023) periods. Additionally, a retrospective analysis of 503 HCV-Ab-positive women diagnosed between 2015 and 2024 was performed, together with a recall of the patients for RNA testing and treatment. The post-intervention rates for screening rose from 41.5% to 66.2%, while those for RNA testing increased from 45.9% to 97.9%, and treatment from 52.6% to 97.3% (all <i>p</i> < 0.001). Among the 503 historical cases, 337 (67.0%) returned for follow-up, with 92.5% completing RNA testing (312/337), 65.1% found to be RNA-positive (203/312) and 91.3% began treatment (185/203). Of these, 98.9% (183/185) achieved SVR12 after direct-acting antiviral therapy. Another 124 (24.7%) agreed to future testing. These findings demonstrated that targeted interventions significantly improve the rates of HCV diagnosis and treatment in women of childbearing age, enabling early detection and reducing the risk of transmission. This model offered a practical approach to eliminating HCV in this population, fulfilling the ‘treatment as prevention’ goal.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics of Patients and Factors Associated With the Development of Hepatitis C Virus-Associated Hepatocellular Carcinoma in an Urban, Primary-Care Based Hepatitis C Clinic 城市丙型肝炎初级保健诊所丙型肝炎病毒相关肝细胞癌患者特征及相关因素

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-18 DOI: 10.1111/jvh.70169

Kathryn Thompson, James Thompson, Lesley S. Miller

{"title":"Characteristics of Patients and Factors Associated With the Development of Hepatitis C Virus-Associated Hepatocellular Carcinoma in an Urban, Primary-Care Based Hepatitis C Clinic","authors":"Kathryn Thompson, James Thompson, Lesley S. Miller","doi":"10.1111/jvh.70169","DOIUrl":"10.1111/jvh.70169","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic hepatitis C virus infection (HCV) is one of the leading causes of hepatocellular carcinoma (HCC) in the United States. Using a retrospective cross-sectional analysis, this study identified patient characteristics and factors associated with the development of HCV-associated HCC in 113 patients seen in the primary care-based HCV clinic in Grady Memorial Hospital, a public, safety-net healthcare facility in Atlanta, Georgia from October 2013 to November 2024. The study population was comprised of mostly African American men with high rates of polysubstance use, 96.5% of whom had cirrhosis. Patients treated for HCV prior to HCC diagnosis were older at HCC diagnosis (mean difference 3.248, <i>p</i>-value 0.037), had a longer latency period between HCV and HCC diagnoses (mean difference 38.740, <i>p</i>-value 0.002), had prior HCC screening (mean difference 0.547, <i>p</i>-value 0.000), and less time from last HCC screening to HCC diagnosis (mean difference −25.332, <i>p</i>-value 0.012), and had a lower Child-Pugh Score at time of HCC diagnosis (mean difference −0.300, <i>p</i>-value 0.036) compared to patients who were not treated for HCV. For patients who achieved SVR prior to HCC, HCV genotype 1 was associated with longer time to HCC diagnosis (<i>p</i>-value 0.030), and a higher FIB-4 index at the time of achieving SVR and longer knowledge of HCV infection were associated with shorter time to developing HCC (<i>p</i>-value 0.003; <i>p</i>-value 0.044). Ultimately, this study highlights the importance of understanding risk factors for HCV-associated HCC in underserved populations which could help providers tailor their approach to mitigate the risk of HCC.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147474270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological Considerations in Prevalence Meta-Analysis of Hepatitis B Among Migrants 流动人口乙型肝炎患病率荟萃分析的方法学考虑。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-18 DOI: 10.1111/jvh.70171

Hemant Singh Thakur, Vikas Yadav

引用次数: 0

Changing Pattern of HDV Infection in Italy Over 40 Years; the Current Scenario and the Impending Challenge 40年来意大利人HDV感染的变化当前形势和即将到来的挑战。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-17 DOI: 10.1111/jvh.70172

Gian Paolo Caviglia, Tommaso Stroffolini

引用次数: 0

Co-Administration of Hepatitis C Direct-Acting Antivirals and Enzyme-Inducing Antiepileptic Drugs: Real-World Experience From a Multi-Centre Case Series 丙型肝炎直接作用抗病毒药物和酶诱导抗癫痫药物的共同管理：来自多中心病例系列的真实世界经验。

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-17 DOI: 10.1111/jvh.70168

R. Harrison, S. Patel, F. Marra, A. Francisco, H. Boothman, Y. Kim, R. Kamiri-Ngugi, J. Lacey, J. Henry, A. Boyle

{"title":"Co-Administration of Hepatitis C Direct-Acting Antivirals and Enzyme-Inducing Antiepileptic Drugs: Real-World Experience From a Multi-Centre Case Series","authors":"R. Harrison, S. Patel, F. Marra, A. Francisco, H. Boothman, Y. Kim, R. Kamiri-Ngugi, J. Lacey, J. Henry, A. Boyle","doi":"10.1111/jvh.70168","DOIUrl":"10.1111/jvh.70168","url":null,"abstract":"<div>\u0000 \u0000 <p>The management of hepatitis C virus (HCV) infection in patients requiring ongoing enzyme-inducing antiepileptic drugs (eiAEDs) presents a therapeutic challenge due to potential drug–drug interactions with direct-acting antivirals (DAAs). Evidence regarding DAA treatment efficacy in this context remains limited. This case series examined the outcomes of patients with HCV who continued their eiAED therapy while being treated with conventional regimens of DAAs. A total of 23 patients with HCV were treated with standard doses and durations of HCV DAAs in combination with eiAEDs. High treatment adherence was reported for 19 (82.6%) patients and 21 (91.3%) achieved sustained virological response; two were lost to follow-up. Despite potential for reduced DAA levels, no virological failures or serious adverse events were observed in patients attending follow-up. This represents the largest reported single case series involving concomitant use of eiAEDs and DAAs. The findings provide reassurance that standard-dose DAA treatment can be effective even when co-administered with eiAEDs.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis HBV RNA预测接受NAs治疗的慢性乙型肝炎患者停药复发的风险：一项系统综述和荟萃分析

IF 2.3 3区医学

Journal of Viral Hepatitis Pub Date : 2026-03-13 DOI: 10.1111/jvh.70167

Dong-Hui Wang, Jia-Lan Wang, Su-Wen Jiang, Ai-Wu Zhou, Meng-Han Jin, Hao-Jin Zhang, Shi-Qi Yang, Shi-Yang Fan, Ai-Rong Hu

{"title":"HBV RNA Predicts the Risk of Off-Treatment Relapse in Chronic Hepatitis B Patients With NAs Therapy: A Systematic Review and Meta-Analysis","authors":"Dong-Hui Wang, Jia-Lan Wang, Su-Wen Jiang, Ai-Wu Zhou, Meng-Han Jin, Hao-Jin Zhang, Shi-Qi Yang, Shi-Yang Fan, Ai-Rong Hu","doi":"10.1111/jvh.70167","DOIUrl":"10.1111/jvh.70167","url":null,"abstract":"<p>Since there are currently few antiviral drugs that can effectively reduce hepatitis B surface antigen levels, the recurrence rate remains high in patients with chronic hepatitis B (CHB) after discontinuing nucleoside analogues (NAs) treatment. This study aims to provide recommendations for monitoring relapse after treatment cessation, while also elucidating the significance of HBV RNA in predicting relapse in CHB patients. Studies published between 2019 and 2025 were searched using PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang, and Cqvip. There are 21 cohort studies included and 2043 individuals involved. In our study, HBV RNA-positive individuals had a 1.9-fold higher viral relapse (VR) rate and a 2.26-fold higher clinical relapse (CR) rate compared to negative patients (all <i>p</i> < 0.0001). Subgroup analyses indicated that HBeAg positive at baseline was associated with higher rates of CR (<i>p</i> = 0.006) and no significant correlation between longer follow-up period following the cessation of NAs therapy (≥ 2 years) and higher VR or CR. For each log10 copies/ml increase in HBV RNA levels at discontinuation, there was a 1.32-fold increase in VR and a 1.37-fold increase in CR (all <i>p</i> < 0.0001). Our findings evaluated the relationship between HBV RNA status and levels at the time of NAs discontinuation and post-discontinuation relapse, highlighting HBV RNA as a helpful post-treatment biomarker for predicting relapse. HBV RNA surveillance is essential for patients discontinuing therapy following NAs, particularly for those who are HBeAg-positive at baseline.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"33 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0